- When independently validated clinical performance is required
- If procurement criteria mandate peer-reviewed clinical studies, published sensitivity/specificity metrics, or regulatory clearance for diagnostic claims, the vendor's accessible public materials do not provide sufficient evidence.
- When "FDA Registered" is being used as a substitute for FDA clearance or approval
- Establishment registration is not equivalent to device clearance or approval. Organizations that equate registration with FDA-reviewed clearance should confirm the specific regulatory status and intended use claims.
- When predictable pricing and packaged enterprise terms are required
- Provider and device deployments appear to be quote-based and routed through demos; organizations needing standard, published pricing and package SKUs may prefer vendors with transparent pricing.
- When mature, publicly documented enterprise controls are a procurement requirement
- SOC 2, ISO 27001, and HIPAA compliance are asserted by the vendor but supporting artifacts were not publicly located; organizations that require a published trust center, subprocessors list, and downloadable policies may prefer vendors with those materials readily available.
- Public evidence gaps
- No published provider/device pricing was located.
- No publicly downloadable SOC 2 report, ISO certificate metadata, or HIPAA documentation/BAA details were discovered in this research.
- No vendor listing on major B2B review platforms (G2, TrustRadius, Capterra) was identified.
- Marketing-claim ambiguity to resolve
- The vendor uses language such as "FDA Registered" on product pages; organizations should confirm whether the registration relates to establishment registration only or to a cleared/approved device and verify any regulatory claims in relevant databases.
- Roadmap and R&D notes
- Public social posts and company updates suggest R&D activity on a portable dermoscopy unit integrated with the vendor ecosystem. Timing and availability were not documented publicly.